Pangea Laboratory has announced a partnership with Unilabs to introduce a non-invasive epigenetic test, the Bladder CARE Assay, in Switzerland.
The cancer assay uses DNA methylation biomarkers to check for bladder cancer and upper tract urothelial carcinoma (UTUC) from urine samples, which can be collected in the at-home setting using the Pangea collection device.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Through this collaboration, the companies aim to enhance cancer diagnostics in Switzerland, with plans to expand the assay’s rollout throughout Europe.
Unilabs Switzerland pathology, genetics and oncology Patrick Bornand head said: “Through this strategic partnership with Pangea Laboratory, Unilabs reinforces its commitment to driving innovation in diagnostics, bringing Bladder CARE to Switzerland as a next-generation solution that empowers early detection and advances patient care.”
The FDA previously granted breakthrough device designation for the Bladder CARE Assay.
This assay is said to have high sensitivity, specificity, and negative predictive value (NPV) exceeding 93% for bladder cancer and UTUC, together with quantitative results.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe results from this assay are intended to be used with existing diagnostic procedures, aiding in the initial diagnosis of bladder cancer and UTUC among patients with haematuria and suspected cases of these cancers.
Pangea Laboratory COO Dr Yap Ching Chew said: “Pangea Laboratory is committed to delivering non-invasive healthcare solutions that reduce patient burden while delivering highly accurate results. We are happy that the Unilabs team shares our vision and the belief that Bladder CARE sets a new standard in the diagnosis of bladder cancer and UTUC.”
